IN2014DN09173A - - Google Patents

Info

Publication number
IN2014DN09173A
IN2014DN09173A IN9173DEN2014A IN2014DN09173A IN 2014DN09173 A IN2014DN09173 A IN 2014DN09173A IN 9173DEN2014 A IN9173DEN2014 A IN 9173DEN2014A IN 2014DN09173 A IN2014DN09173 A IN 2014DN09173A
Authority
IN
India
Prior art keywords
compositions
compounds
virus infections
infections
useful
Prior art date
Application number
Inventor
Dustin Siegel
David Sperandio
Hai Yang
Michael Sangi
Jay P Parrish
I Hon Chung HU
Richard L Mackman
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of IN2014DN09173A publication Critical patent/IN2014DN09173A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
IN9173DEN2014 2012-04-17 2013-04-17 IN2014DN09173A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625480P 2012-04-17 2012-04-17
PCT/US2013/037001 WO2013158776A1 (en) 2012-04-17 2013-04-17 Compounds and methods for antiviral treatment

Publications (1)

Publication Number Publication Date
IN2014DN09173A true IN2014DN09173A (en) 2015-07-10

Family

ID=48190648

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9173DEN2014 IN2014DN09173A (en) 2012-04-17 2013-04-17

Country Status (24)

Country Link
US (4) US8980878B2 (en)
EP (1) EP2838900B1 (en)
JP (3) JP2015516976A (en)
KR (2) KR102181318B1 (en)
CN (2) CN106986869A (en)
AU (1) AU2013249280B2 (en)
CA (1) CA2870024C (en)
CY (1) CY1122292T1 (en)
DK (1) DK2838900T3 (en)
EA (1) EA027855B1 (en)
ES (1) ES2750153T3 (en)
HK (1) HK1209745A1 (en)
HR (1) HRP20191754T1 (en)
HU (1) HUE045727T2 (en)
IL (1) IL235062A0 (en)
IN (1) IN2014DN09173A (en)
LT (1) LT2838900T (en)
MX (1) MX355781B (en)
NZ (1) NZ701647A (en)
PL (1) PL2838900T3 (en)
PT (1) PT2838900T (en)
SG (2) SG11201406736VA (en)
SI (1) SI2838900T1 (en)
WO (1) WO2013158776A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54761B1 (en) 2010-06-24 2016-10-31 Gilead Sciences PYRAZOLO [1,5-A] PYRIMIDINES I-TRIAZINES AS ANTIVIRAL AGENTS
JP6122868B2 (en) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド Pyrazolo [1,5-A] pyrimidine as an antiviral agent
CN106986869A (en) * 2012-04-17 2017-07-28 吉利德科学公司 Compounds and methods for for antiviral therapy
HK1225716A1 (en) 2013-08-21 2017-09-15 Alios Biopharma, Inc. Antiviral compounds
UA119151C2 (en) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
WO2016055656A1 (en) * 2014-10-10 2016-04-14 Ablynx N.V. Methods of treating rsv infections
CN107207512B (en) * 2014-12-08 2019-09-10 爱尔兰詹森科学公司 Tricyclic pyrazole simultaneously [1, the 5-A] pyrimidine derivatives that there is the piperidines of inhibitory activity to replace the duplication of Respiratory Syncytial Virus(RSV) (RSV)
ES2704740T3 (en) 2014-12-08 2019-03-19 Janssen Sciences Ireland Uc Derivatives of pyrazolo [1,5-a] pyrimidine substituted with piperidine with inhibitory activity on the replication of the respiratory syncytial virus (vsr)
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MA41614A (en) 2015-02-25 2018-01-02 Alios Biopharma Inc ANTIVIRAL COMPOUNDS
JP2018076234A (en) * 2015-03-16 2018-05-17 大正製薬株式会社 Pyrazolo [1,5-a] pyrimidine compounds
JO3637B1 (en) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
FI3442977T3 (en) 2016-04-15 2023-09-26 Blueprint Medicines Corp Inhibitors of activin receptor-like kinase
ES2989988T3 (en) 2016-05-10 2024-11-28 C4 Therapeutics Inc Heterocyclic degronimers for the degradation of target proteins
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CN109562113A (en) 2016-05-10 2019-04-02 C4医药公司 Spiro degron for target protein degradation
PL3523274T3 (en) 2016-10-06 2026-03-09 Orbus Therapeutics, Inc. Formulations for administration of eflornithine
CN110769822A (en) 2017-06-20 2020-02-07 C4医药公司 N/O-linked degron and degron bodies for protein degradation
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
KR102747388B1 (en) * 2017-10-16 2024-12-26 브리스톨-마이어스 스큅 컴퍼니 Cyclic dinucleotides as anticancer agents
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
TW201932470A (en) * 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 Pyrazolopyrimidines having activity against RSV
FI3706762T3 (en) 2017-12-07 2024-12-13 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
ES2957316T3 (en) 2018-04-23 2024-01-17 Janssen Sciences Ireland Unlimited Co Heteroaromatic compounds that have activity against RSV
EP3903788A4 (en) * 2018-12-27 2022-09-07 Taisho Pharmaceutical Co., Ltd. MACROCYCLIC PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND
KR20220140515A (en) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. Substituted pyrazolo-pyrimidines and uses thereof
CN116528850B (en) 2020-10-28 2025-08-22 盐野义制药株式会社 Amide derivatives with antiviral activity
CN113264929B (en) * 2021-05-02 2023-10-10 润生药业有限公司 Preparation method of tiotropium bromide
JP7454729B2 (en) * 2022-04-27 2024-03-22 塩野義製薬株式会社 Pharmaceutical composition containing an amide derivative with antiviral activity

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (en) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (en) 1974-07-15 1977-07-20 Isf Spa APPARATUS FOR INHALATIONS
SE438261B (en) 1981-07-08 1985-04-15 Draco Ab USE IN A DOSHALATOR OF A PERFORED MEMBRANE
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (en) 1985-04-12 1987-02-09 Draco Ab INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
DE69230613T2 (en) 1991-07-02 2000-12-28 Inhale Inc METHOD AND DEVICE FOR DISPENSING MEDICINES IN AEROSOL FORM
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
US5543413A (en) 1994-02-25 1996-08-06 Regents Of The University Of Michigan Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action
JPH10504808A (en) 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
BR9908004A (en) 1998-02-17 2001-12-18 Tularik Inc Compound, composition and method for preventing or suppressing a viral infection
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
TWI225488B (en) 1999-12-21 2004-12-21 Janssen Pharmaceutica Nv Derivatives of homopiperidinyl substituted benzimidazole analogues
DE60235114D1 (en) * 2001-11-01 2010-03-04 Icagen Inc PYRAZOLAMIDES FOR USE IN THE TREATMENT OF PAIN
AU2003220190A1 (en) 2002-03-13 2003-09-29 Pharmacia & Upjohn Company Llc Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
ES2287476T3 (en) 2002-05-10 2007-12-16 Smithkline Beecham Corporation REPLACED PIRAZOLOPIRIMIDINAS.
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
DE10247271A1 (en) 2002-10-10 2004-08-26 Grünenthal GmbH Use of new and known 7-(methyl or trifluoromethyl)-imidazo-(1,2-a)-pyridines as nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, neurodegenerative diseases, inflammatory pain, diabetes or cancer
KR20060127909A (en) 2003-12-24 2006-12-13 비오타 사이언티픽 매니지먼트 피티와이 엘티디 Polycyclic materials for the treatment of respiratory multinuclear virus infection
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
TW200831084A (en) 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
AU2008334948B2 (en) 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
WO2009079011A1 (en) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
CN101959889A (en) 2008-02-26 2011-01-26 诺瓦提斯公司 Heterocyclic compounds as inhibitors of CXCR2
CN102046179B (en) 2008-04-09 2015-01-14 英菲尼提制药公司 Inhibitors of fatty acid amide hydrolase
WO2010033701A2 (en) 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
EP2182081B1 (en) 2008-10-29 2014-01-22 Neue Materialien Bayreuth GmbH Method for thermal treatment of a coated steel sheet body
KR101784830B1 (en) 2008-12-03 2017-10-16 프레시디오 파마슈티칼스, 인코포레이티드 Inhibitors of hcv ns5a
US8609696B2 (en) 2008-12-18 2013-12-17 Boehringer Ingelheim International Gmbh Serotonin 5-HT2B receptor inhibitors
CN102264737A (en) 2008-12-23 2011-11-30 雅培制药有限公司 Anti-viral compounds
TWI438200B (en) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Hepatitis c virus inhibitors
CN102427731B (en) 2009-02-27 2015-05-13 英安塔制药有限公司 Hepatitis c virus inhibitors
US8889674B2 (en) 2009-03-05 2014-11-18 Shionogi & Co., Ltd. Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
KR20100101055A (en) * 2009-03-07 2010-09-16 주식회사 메디젠텍 Composition for treating or preventing nuclear export of gsk3- mediated disease including compound for inhibiting nuclear export of gsk3
UA118080C2 (en) 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані ANTI-VIRUS COMPOUNDS
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2010280712B2 (en) * 2009-08-07 2015-10-22 Janssen Sciences Ireland Uc Bis-benzimidazole derivatives as hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EP2575866A4 (en) * 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
RS54761B1 (en) 2010-06-24 2016-10-31 Gilead Sciences PYRAZOLO [1,5-A] PYRIMIDINES I-TRIAZINES AS ANTIVIRAL AGENTS
PH12013500035A1 (en) * 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
JP6122868B2 (en) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド Pyrazolo [1,5-A] pyrimidine as an antiviral agent
CN106986869A (en) 2012-04-17 2017-07-28 吉利德科学公司 Compounds and methods for for antiviral therapy

Also Published As

Publication number Publication date
SG10201610166VA (en) 2017-01-27
KR20200044971A (en) 2020-04-29
US10174038B2 (en) 2019-01-08
JP2015516976A (en) 2015-06-18
US20170342079A1 (en) 2017-11-30
PL2838900T3 (en) 2020-02-28
EP2838900A1 (en) 2015-02-25
US20170029427A1 (en) 2017-02-02
NZ701647A (en) 2016-05-27
IL235062A0 (en) 2014-12-31
EA027855B1 (en) 2017-09-29
MX2014012450A (en) 2015-04-08
CA2870024C (en) 2020-04-07
US20150238501A1 (en) 2015-08-27
US9504689B2 (en) 2016-11-29
AU2013249280B2 (en) 2017-10-12
CN104583211A (en) 2015-04-29
KR102102283B1 (en) 2020-04-21
ES2750153T3 (en) 2020-03-25
DK2838900T3 (en) 2019-10-14
HRP20191754T1 (en) 2020-01-24
EA201491889A1 (en) 2015-03-31
HUE045727T2 (en) 2021-12-28
AU2013249280A1 (en) 2014-11-06
KR20140145615A (en) 2014-12-23
SI2838900T1 (en) 2019-10-30
CY1122292T1 (en) 2021-01-27
HK1207076A1 (en) 2016-01-22
MX355781B (en) 2018-04-30
PT2838900T (en) 2019-11-15
CN106986869A (en) 2017-07-28
HK1209745A1 (en) 2016-04-08
WO2013158776A1 (en) 2013-10-24
SG11201406736VA (en) 2015-03-30
JP2018095657A (en) 2018-06-21
JP6291103B2 (en) 2018-03-14
JP2017128596A (en) 2017-07-27
US20130273037A1 (en) 2013-10-17
US8980878B2 (en) 2015-03-17
KR102181318B1 (en) 2020-11-20
EP2838900B1 (en) 2019-08-21
CA2870024A1 (en) 2013-10-24
LT2838900T (en) 2019-11-11

Similar Documents

Publication Publication Date Title
IN2014DN09173A (en)
IN2014MN02652A (en)
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
IL230458A0 (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
IN2014MN02657A (en)
IN2014MN02658A (en)
ZA201308746B (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MY173422A (en) Purine derivatives for the treatment of viral infections
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12015500355B1 (en) Compounds for the treatment of paramoxyvirus viral infections
AU2012358805A8 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
HK1217092A1 (en) Therapeutic compounds and uses thereof
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
ZA201400442B (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses